JP2018500332A - 中枢神経系新生物における免疫チェックポイント阻害剤の使用 - Google Patents

中枢神経系新生物における免疫チェックポイント阻害剤の使用 Download PDF

Info

Publication number
JP2018500332A
JP2018500332A JP2017532140A JP2017532140A JP2018500332A JP 2018500332 A JP2018500332 A JP 2018500332A JP 2017532140 A JP2017532140 A JP 2017532140A JP 2017532140 A JP2017532140 A JP 2017532140A JP 2018500332 A JP2018500332 A JP 2018500332A
Authority
JP
Japan
Prior art keywords
antibody
antigen binding
binding site
administered
ctla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017532140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500332A5 (enExample
Inventor
ウラディミール・コリック
シンタ・チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2018500332A publication Critical patent/JP2018500332A/ja
Publication of JP2018500332A5 publication Critical patent/JP2018500332A5/ja
Priority to JP2021131637A priority Critical patent/JP2021181482A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017532140A 2014-12-16 2015-12-16 中枢神経系新生物における免疫チェックポイント阻害剤の使用 Pending JP2018500332A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021131637A JP2021181482A (ja) 2014-12-16 2021-08-12 中枢神経系新生物における免疫チェックポイント阻害剤の使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462092783P 2014-12-16 2014-12-16
US62/092,783 2014-12-16
US201562261130P 2015-11-30 2015-11-30
US62/261,130 2015-11-30
PCT/US2015/066177 WO2016100561A2 (en) 2014-12-16 2015-12-16 Use of immune checkpoint inhibitors in central nervous systems neoplasms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021131637A Division JP2021181482A (ja) 2014-12-16 2021-08-12 中枢神経系新生物における免疫チェックポイント阻害剤の使用

Publications (2)

Publication Number Publication Date
JP2018500332A true JP2018500332A (ja) 2018-01-11
JP2018500332A5 JP2018500332A5 (enExample) 2019-01-31

Family

ID=56127849

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017532140A Pending JP2018500332A (ja) 2014-12-16 2015-12-16 中枢神経系新生物における免疫チェックポイント阻害剤の使用
JP2021131637A Pending JP2021181482A (ja) 2014-12-16 2021-08-12 中枢神経系新生物における免疫チェックポイント阻害剤の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021131637A Pending JP2021181482A (ja) 2014-12-16 2021-08-12 中枢神経系新生物における免疫チェックポイント阻害剤の使用

Country Status (9)

Country Link
US (3) US20180133313A1 (enExample)
EP (1) EP3233123A4 (enExample)
JP (2) JP2018500332A (enExample)
CN (1) CN106999590A (enExample)
BR (1) BR112017010101A2 (enExample)
CA (1) CA2969338A1 (enExample)
MX (1) MX2017007390A (enExample)
RU (1) RU2726996C1 (enExample)
WO (1) WO2016100561A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021132636A1 (enExample) * 2019-12-27 2021-07-01

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
WO2016176503A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
EP3288980B1 (en) * 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
US11209441B2 (en) 2016-04-05 2021-12-28 Bristol-Myers Squibb Company Cytokine profiling analysis
WO2018029124A1 (en) * 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
GB201618291D0 (en) * 2016-10-28 2016-12-14 Bergen Teknologioverf�Ring As Novel immunotherapeutic treatments for tumours
IL317919A (en) * 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
DE102017119868B4 (de) * 2017-07-12 2021-05-27 Bruker Daltonik Gmbh Feuchtestabilisierung bei der Präparation von Proben für die Spektrometrie
JP7159007B2 (ja) * 2017-11-01 2022-10-24 小野薬品工業株式会社 脳腫瘍の治療のための医薬
US12668635B1 (en) 2017-11-21 2026-06-30 Arcus Biosciences, Inc. Methods of treating solid tumors using an anti-PD-1 antibody or a fragment thereof
EP3774911A1 (en) * 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
MX2020012939A (es) 2018-05-31 2021-02-15 Ono Pharmaceutical Co Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios.
EP3941467A4 (en) * 2019-03-19 2022-12-21 ChemoCentryx, Inc. COMBINATION THERAPY WITH A CHEMOKINE RECEPTOR-2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR
JP7562645B2 (ja) * 2019-09-10 2024-10-07 ノボキュア ゲーエムベーハー がん細胞への交流電場の印加及びチェックポイント阻害剤の投与によってがん細胞の生存率を低下させる方法
EP4076669A4 (en) * 2019-12-19 2024-01-10 Board of Regents, The University of Texas System METHOD FOR TREATING GLIOBLASTOMA
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
EP4149512A4 (en) 2020-05-12 2024-06-05 Board of Regents, The University of Texas System Methods for treating glioblastoma
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US20230365690A1 (en) * 2020-08-07 2023-11-16 Northwestern University Methods of treating malignant glioblastoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177624A2 (en) * 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201500417A1 (ru) * 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010036959A2 (en) * 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
RU2402360C1 (ru) * 2009-07-08 2010-10-27 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Способ лечения злокачественной глиомы головного мозга
CN102178676B (zh) * 2011-04-29 2012-07-25 山东大学 一种治疗脑胶质瘤的药物组合物
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US10392442B2 (en) * 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177624A2 (en) * 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. CLIN. PHARMACOL., (2009), 49, [9], P.1012-1024, JPN6020020558, ISSN: 0004485963 *
脳神経外科速報, (2009), 19, [4], P.434-440, JPN6019038140, ISSN: 0004485962 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021132636A1 (enExample) * 2019-12-27 2021-07-01
WO2021132636A1 (ja) * 2019-12-27 2021-07-01 特定非営利活動法人Ｎｏｒｔｈ Ｅａｓｔ Ｊａｐａｎ Ｓｔｕｄｙ Ｇｒｏｕｐ がん治療方法及び医薬
JP7822568B2 (ja) 2019-12-27 2026-03-03 特定非営利活動法人North East Japan Study Group がん治療方法及び医薬

Also Published As

Publication number Publication date
US20240238416A1 (en) 2024-07-18
US20180133313A1 (en) 2018-05-17
EP3233123A2 (en) 2017-10-25
BR112017010101A2 (pt) 2018-01-02
WO2016100561A3 (en) 2016-08-18
EP3233123A4 (en) 2018-05-09
WO2016100561A2 (en) 2016-06-23
RU2726996C1 (ru) 2020-07-17
MX2017007390A (es) 2017-11-06
US20210000953A1 (en) 2021-01-07
CA2969338A1 (en) 2016-06-23
JP2021181482A (ja) 2021-11-25
CN106999590A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
US20240238416A1 (en) Use of immune checkpoint inhibitors in central nervous systems neoplasms
JP7163260B2 (ja) 腫瘍を処置するための抗ｌａｇ－３抗体と抗ｐｄ－１抗体との組合せ
ES2981569T3 (es) Métodos de tratamiento usando terapia celular adoptiva
US20250011466A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
JP6533270B2 (ja) がんを処置するための抗ｋｉｒ抗体と抗ｐｄ−１抗体との組み合わせ
JP2020015737A (ja) 血液悪性腫瘍を処置するための抗ｌａｇ−３抗体
KR20180011250A (ko) T 세포 요법을 위해 환자를 컨디셔닝하는 방법
JP7308190B2 (ja) 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置
JP2019503387A (ja) 抗ｐｄ−１抗体および別の抗癌剤の組合せを用いる肺癌の処置法
KR20220005075A (ko) 키메라 항원 수용체 면역요법의 투여 방법
WO2017205213A1 (en) Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer
JP2024519450A (ja) 抗ガレクチン－９抗体及びその治療的使用
JP2024519449A (ja) がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用
JP2025522729A (ja) ガレクチン－９を阻害する抗体を用いた悪性血液疾患の処置
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
JP2026513770A (ja) 抗ｃｔｌａ４抗体を使用して黒色腫を治療する方法
TW202436335A (zh) 治療表現ｄｌｌ３的癌症之方法
EP4423135A1 (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
HK40070586A (en) Methods of administering chimeric antigen receptor immunotherapy
EA048407B1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200915

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210413